IP
IndiaPulse

Tatva Chintan Pharma Chem Limited (TATVA)

Small Cap

Industrials stocks · Small cap · NSE

Tatva Chintan Pharma Chem Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹1,678.5
+82.30 · +5.16%
Quote04 Sept, 03:54 pm IST
Fundamentals05 Sept 2026 · screener
Score05 Sept, 10:20 pm IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.4 (n=540)
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is consistent.

Suggested next step
Research, do not rush
The four lenses are not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
OVERVALUED
21

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Mixed Trust
67

low confidence · 0/0 claims checked

Technical
Bullish
63

Timing lens: price trend and sector relative strength.

Result consistency
consistent
80

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 30 Jun 2026

Excellent · 100/100

Rev +43% YoY · PAT +129% YoY · margin expansion · +25% QoQ · operating leverage

Filed 17 Jul 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹167 Cr+42.7%+24.6%
EBITDA₹32 Cr+88.2%+14.3%
Operating margin19.0%+400 bps-200 bps
PAT₹16 Cr+128.6%+60.0%
PAT margin9.6%+360 bps+212 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business & thesis

Growth engines, tailwinds/headwinds, and risk radar from management commentary

Business and thesis

Issuer presentation review pending

Tatva Chintan Pharma Chem Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Management accountability

What management said, and what results must prove

Technical timing lens

Trend score and candlestick chart

63Bullish

full bull SMA stack · MACD − · near 52W high

Stock trend: 73
Sector RS: 48
Sector 3M: -1.6% vs Nifty -1.5%

Technical chart

TATVAdaily · 1Y · AUTO+48.3%
Latest close ₹1678.50 on 2026-09-04
Bar
+4.3%
RSI
57
MACD hist
-8.61
52W pos
81%
2026-09-04O ₹1609.90H ₹1688.00L ₹1580.10C ₹1678.50Vol 85,803 sh
₹1.00k₹1.22k₹1.44k₹1.66k₹1.88k52H1678.502026-032026-06VolRSIMACD2026-032026-042026-062026-072026-09
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal

Daily technical trend read

Bullish setup

Trend is constructive — long-term uptrend intact. RSI 57.

  • Price > SMA20 > SMA50 > SMA200 — full bullish stack.
  • SMA20 roughly flat — short-term momentum stalled.
  • RSI(14) at 57 — rising, no extreme reading.
  • MACD below signal but histogram contracting — bearish momentum easing.
  • 9% off 52W high · 72% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Valuation & score drivers

U-Score 21 · OVERVALUED · pillar breakdown, sector model, fair-value anchor

21U-SCORE
OVERVALUED

Fundamental score breakdown

OVERVALUED
Valuation0/30
Growth5/25
Quality0/20
Balance Sheet10/15
Cash Flow1/10
Piotroski
7/9 (+5)
Penalties
0
Raw sum
21

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

21/100 · OVERVALUED

Positive drivers

  • Piotroski is strong at 7/9.
  • Balance sheet contributes 10/15 to the score.
  • Growth contributes 5/25 to the score.

Main drags

  • Fair-value margin of safety is negative at -1294.2%.
  • Valuation is weaker at 0/30; verify the latest quarterly trend.
  • Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
74.9
PB
5.0
EV/EBITDA
27.7
ROE
5.5%
ROCE
7.2%
FCF Yield
Debt/Equity
0.1
MoS
-1294.2%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 05 Sept 2026
v4.3-runtime-valuation
Final score
21
Previous: 21
Verdict
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1294.2%
Previous: -1294.2%

Score history

12 stored score snapshots. Latest stored move: +0 points.

05 Sept 2026
v4.3-runtime-valuation
21
20
20
20
20
21
21
21
21
21
21
21

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
₹406.33
-313.1% MoS
Growth-justified P/E
5.5
Growth-justified Value
₹120.4
-1294.2% MoS
PEG

Trust score

Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth

Trust Score
67Mixed Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Mixed Trust: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 49th percentile within Industrials. Main check: cash conversion is weak at 43/100.

Healthy Trust Lite: Promoter holding is 72%. Key concern: Only 0 years of positive FCF.

Computed 05 Sept 2026
management-trust-v1
88 docs text-extracted · 40 concalls text-extracted
Score band
Mixed Trust

Usable, but needs evidence. Treat guidance with a margin of safety.

Relative rank
52nd percentile

overall median 67 · Industrials: 49th pctile, median 68 · Small: 56th pctile, median 66

Evidence depth
Financial-only

88 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Mixed Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
48
watch · capital discipline
Results
80
strong · quarterly consistency

Trust positives

  • Promoter holding is 72%.
  • Promoter pledge is zero.
  • 4/4 latest quarters had positive YoY revenue growth.
  • 3/4 latest quarters had positive YoY PAT growth.

Trust risks

  • Only 0 years of positive FCF.
  • ROCE is low at 7.2%.
  • ROE is low at 5.5%.
  • 1 of the latest 4 quarters had PAT decline worse than 25% YoY.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Financials

Full fundamentals table and 10-year revenue / profit / ROE history

Fundamentals

Valuation

P/E
74.90
P/B
5.02
EV/EBITDA
27.71
Market Cap
3926.00Cr

Profitability

ROE
5.54%
ROCE
7.18%
ROA
5.08%
Dividend Y
0.12%

Growth (CAGR)

Revenue 5Y
11.00%
EPS 5Y
-4.00%
Revenue 3Y
6.00%
EPS 3Y
-5.00%

Balance Sheet

Debt/Equity
0.15
Interest Coverage
21.60×
Altman Z
8.25
Book Value
334.00

Cash Flow

FCF Yield
FCF Positive Y
0/5
OCF
31.00 Cr
EPS TTM
21.97

Shareholding

Promoter Hold
72.02%
Promoter Pledge
0.00%
Momentum 52W
81%

Financial History

Updated 5/9/2026

Revenue

₹ Cr
No data

Net Profit

₹ Cr
No data

Return on Equity

%
No data

Peers

Business-comparable names in Industrials, ranked by similarity

Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.